
Salim Abdool Karim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4782683/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	COVID-19: Impact on the HIV and Tuberculosis Response, Service Delivery, and Research in South Africa. Current HIV/AIDS Reports, 2022, 19, 46-53.	3.1	26
2	Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention. Journal of Infectious Diseases, 2022, 226, 510-520.	4.0	13
3	SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host and Microbe, 2022, 30, 154-162.e5.	11.0	153
4	CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women. BMJ Open, 2022, 12, e052880.	1.9	18
5	Mortality in HIV and tuberculosis patients following implementation of integrated HIV-TB treatment: Results from an open-label cluster-randomized trial. EClinicalMedicine, 2022, 44, 101298.	7.1	4
6	Genital immune cell activation and tenofovir gel efficacy: a case-control study. Clinical Infectious Diseases, 2022, , .	5.8	2
7	Pre-infection plasma cytokines and chemokines as predictors of HIV disease progression. Scientific Reports, 2022, 12, 2437.	3.3	6
8	Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis. Antiviral Therapy, 2022, 27, 135965352110675.	1.0	1
9	Age-Restriction of a Validated Risk Scoring Tool Better Predicts HIV Acquisition in South African Women: CAPRISA 004. AIDS and Behavior, 2022, , 1.	2.7	Ο
10	COVID-19 vaccine wastage in the midst of vaccine inequity: causes, types and practical steps. BMJ Global Health, 2022, 7, e009010.	4.7	29
11	Public understanding of science: Communicating in the midst of a pandemic. Public Understanding of Science, 2022, 31, 282-287.	2.8	5
12	Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. The Lancet Global Health, 2022, 10, e961-e969.	6.3	120
13	Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review. Journal of Infectious Diseases, 2021, 223, 370-380.	4.0	50
14	Betamethasone induces potent immunosuppression and reduces HIV infection in a PBMC in vitro model. Journal of Investigative Medicine, 2021, 69, 28-40.	1.6	4
15	Identifying SARS-CoV-2 infections in South Africa: Balancing public health imperatives with saving lives. Biochemical and Biophysical Research Communications, 2021, 538, 221-225.	2.1	12
16	Future scenarios for the COVID-19 pandemic. Lancet, The, 2021, 397, 777-778.	13.7	127
17	Impact of point-of-care testing and treatment of sexually transmitted infections and bacterial vaginosis on genital tract inflammatory cytokines in a cohort of young South African women. Sexually Transmitted Infections, 2021, 97, 555-565.	1.9	8
18	Plasma Biomarkers of Risk of Tuberculosis Recurrence in HIV Co-Infected Patients From South Africa. Frontiers in Immunology, 2021, 12, 631094.	4.8	7

#	Article	IF	CITATIONS
19	SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet, The, 2021, 397, 952-954.	13.7	462
20	Genital and systemic immune effects of the injectable, contraceptive norethisterone enanthate (NETâ€EN), in South African women. American Journal of Reproductive Immunology, 2021, 86, e13411.	1.2	1
21	Priorities for the COVID-19 pandemic at the start of 2021: statement of the Lancet COVID-19 Commission. Lancet, The, 2021, 397, 947-950.	13.7	26
22	Engaging young women in Africa for PrEP use and adherence. Lancet HIV,the, 2021, 8, e122-e123.	4.7	2
23	Commentary title: COVID-19 research, Africa, and global health. Journal of Virus Eradication, 2021, 7, 100030.	0.5	1
24	Appropriate names for COVID-19 variants. Science, 2021, 371, 1215-1215.	12.6	16
25	Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection. Lancet, The, 2021, 397, 1263-1264.	13.7	49
26	Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study. Lancet HIV,the, 2021, 8, e216-e224.	4.7	15
27	New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications. New England Journal of Medicine, 2021, 384, 1866-1868.	27.0	581
28	Institutional and behaviour-change interventions to support COVID-19 public health measures: a review by the Lancet Commission Task Force on public health measures to suppress the pandemic. International Health, 2021, 13, 399-409.	2.0	41
29	Epigenetic Regulation of BST-2 Expression Levels and the Effect on HIV-1 Pathogenesis. Frontiers in Immunology, 2021, 12, 669241.	4.8	4
30	Recent Semen Exposure Impacts the Cytokine Response and Bacterial Vaginosis in Women. Frontiers in Immunology, 2021, 12, 695201.	4.8	7
31	Immunological Correlates of the HIV-1 Replication-Competent Reservoir Size. Clinical Infectious Diseases, 2021, 73, 1528-1531.	5.8	4
32	Transient association between semen exposure and biomarkers of genital inflammation in South African women at risk of HIV infection. Journal of the International AIDS Society, 2021, 24, e25766.	3.0	5
33	HIV incidence trends in Africa: young women at highest risk. Lancet HIV,the, 2021, 8, e389-e390.	4.7	7
34	Exploring discrepant knowledge of partner sexual behaviour to inform self-risk assessment in a high HIV burdened district in rural KwaZulu-Natal. Global Public Health, 2021, , 1-16.	2.0	0
35	Temporal Changes in Vaginal Microbiota and Genital Tract Cytokines Among South African Women Treated for Bacterial Vaginosis. Frontiers in Immunology, 2021, 12, 730986.	4.8	25
36	A clusterâ€randomized controlled trial to improve the quality of integrated HIVâ€tuberculosis services in primary healthcareclinics in South Africa. Journal of the International AIDS Society, 2021, 24, e25803.	3.0	5

#	Article	IF	CITATIONS
37	Audio Interview: Covid-19 in South Africa and a New SARS-CoV-2 Variant. New England Journal of Medicine, 2021, 384, e14.	27.0	3
38	Simplifying TREAtment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes. BMJ Open, 2021, 11, e050116.	1.9	7
39	COVID-19 in Africa: Catalyzing change for sustainable development. PLoS Medicine, 2021, 18, e1003869.	8.4	2
40	ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection. PLoS Pathogens, 2021, 17, e1010046.	4.7	6
41	Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet, The, 2021, 398, 2126-2128.	13.7	1,057
42	Higher mucosal antibody concentrations in women with genital tract inflammation. Scientific Reports, 2021, 11, 23514.	3.3	3
43	HIV pre-exposure prophylaxis implementation in Africa: some early lessons. The Lancet Global Health, 2021, 9, e1634-e1635.	6.3	3
44	Plasma concentration of injectable contraceptive correlates with reduced cervicovaginal growth factor expression in South African women. Mucosal Immunology, 2020, 13, 449-459.	6.0	15
45	Antibody Isotype Switching as a Mechanism to Counter HIV Neutralization Escape. Cell Reports, 2020, 33, 108430.	6.4	16
46	The Impact of Semen Exposure on the Immune and Microbial Environments of the Female Genital Tract. Frontiers in Reproductive Health, 2020, 2, .	1.9	4
47	Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women. Frontiers in Immunology, 2020, 11, 1274.	4.8	1
48	COVID-19 affects HIV and tuberculosis care. Science, 2020, 369, 366-368.	12.6	54
49	Identification of adolescent girls and young women for targeted HIV prevention: a new risk scoring tool in KwaZulu Natal, South Africa. Scientific Reports, 2020, 10, 13017.	3.3	7
50	Lancet COVID-19 Commission Statement on the occasion of the 75th session of the UN General Assembly. Lancet, The, 2020, 396, 1102-1124.	13.7	117
51	Development of a prognostic tool exploring female adolescent risk for HIV prevention and PrEP in rural South Africa, a generalised epidemic setting. Sexually Transmitted Infections, 2020, 96, 47-54.	1.9	12
52	The South African Response to the Pandemic. New England Journal of Medicine, 2020, 382, e95.	27.0	92
53	Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open-label, non-inferiority, randomised controlled trial. Lancet HIV,the, 2020, 7, e229-e237.	4.7	66
54	Putting women in the centre of the global HIV response is key to achieving epidemic control!. Journal of the International AIDS Society, 2020, 23, e25473.	3.0	9

#	Article	IF	CITATIONS
55	Assessing a diagnosis tool for bacterial vaginosis. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1481-1485.	2.9	10
56	Integrating and Interpreting Findings from the Latest Treatment as Prevention Trials. Current HIV/AIDS Reports, 2020, 17, 249-258.	3.1	10
57	Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PCT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial. BMJ Open, 2020, 10, e042247.	1.9	25
58	Acceptability of HIV self-testing among men and women in KwaZulu-Natal, SouthÂAfrica. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 186-192.	1.2	50
59	Diminished HIV Infection of Target CD4+ T Cells in a Toll-Like Receptor 4 Stimulated in vitro Model. Frontiers in Immunology, 2019, 10, 1705.	4.8	10
60	HIV-1 Epidemic Control — Insights from Test-and-Treat Trials. New England Journal of Medicine, 2019, 381, 286-288.	27.0	54
61	AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region. Molecular Therapy - Methods and Clinical Development, 2019, 14, 100-112.	4.1	24
62	Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis. Viruses, 2019, 11, 569.	3.3	2
63	Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial. BMJ Open, 2019, 9, e030283.	1.9	12
64	HIV incidence rates in adolescent girls and young women in sub-Saharan Africa. The Lancet Global Health, 2019, 7, e1470-e1471.	6.3	71
65	The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. Science Translational Medicine, 2019, 11, .	12.4	141
66	Integrated provision of topical preâ€exposure prophylaxis in routine family planning services in South Africa: a nonâ€inferiority randomized controlled trial. Journal of the International AIDS Society, 2019, 22, e25381.	3.0	13
67	Trends in HIV Prevention, Treatment, and Incidence in a Hyperendemic Area of KwaZulu-Natal, South Africa. JAMA Network Open, 2019, 2, e1914378.	5.9	33
68	Mechanisms of sexually transmitted infectionâ€induced inflammation in women: implications for <scp>HIV</scp> risk. Journal of the International AIDS Society, 2019, 22, e25346.	3.0	45
69	Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy. Frontiers in Microbiology, 2019, 10, 1441.	3.5	46
70	The genital tract and rectal microbiomes: their role in HIV susceptibility and prevention in women. Journal of the International AIDS Society, 2019, 22, e25300.	3.0	43
71	Asymptomatic Bacterial Vaginosis in Pregnancy and Missed Opportunities for Treatment: A Cross-Sectional Observational Study. Infectious Diseases in Obstetrics and Gynecology, 2019, 2019, 1-7.	1.5	12
72	Who is sexually active? Using a multi-component sexual activity profile (MSAP) to explore, identify and describe sexually-active high-school students in rural KwaZulu-Natal, South Africa. BMC Public Health, 2019, 19, 317.	2.9	3

#	Article	IF	CITATIONS
73	Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000–2016: A Pooled Sequence Analysis. EClinicalMedicine, 2019, 9, 26-34.	7.1	51
74	Evidence for both Intermittent and Persistent Compartmentalization of HIV-1 in the Female Genital Tract. Journal of Virology, 2019, 93, .	3.4	9
75	Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway. Frontiers in Immunology, 2019, 10, 2875.	4.8	20
76	lgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. PLoS Pathogens, 2019, 15, e1008064.	4.7	66
77	HPV infection and the genital cytokine milieu in women at high risk of HIV acquisition. Nature Communications, 2019, 10, 5227.	12.8	40
78	Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies. Journal of Virology, 2019, 93, .	3.4	13
79	Moderate-to-High Levels of Pretreatment HIV Drug Resistance in KwaZulu-Natal Province, South Africa. AIDS Research and Human Retroviruses, 2019, 35, 129-138.	1.1	21
80	<i>â€~You'll always stay right':</i> understanding vaginal products and the motivations for use among adolescent and young women in rural KZN. Culture, Health and Sexuality, 2019, 21, 95-107.	1.8	2
81	Improving survival with tuberculosis & HIV treatment integration: A mini-review. Indian Journal of Medical Research, 2019, 150, 131.	1.0	6
82	Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women. Nature Medicine, 2018, 24, 491-496.	30.7	123
83	Identification and validation of a multiâ€assay algorithm for crossâ€sectional HIV incidence estimation in populations with subtype C infection. Journal of the International AIDS Society, 2018, 21, e25082.	3.0	26
84	Integrin α ₄ β ₇ expression on peripheral blood CD4 ⁺ T cells predicts HIV acquisition and disease progression outcomes. Science Translational Medicine, 2018, 10, .	12.4	85
85	Clinic-Based Evaluation of a Point-of-Care Creatinine Assay to Screen for Renal Impairment Among HIV-Positive Patients Receiving Tenofovir Disoproxil Fumarate. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, e36-e39.	2.1	4
86	Acceptability of Early Antiretroviral Therapy Among South African Women. AIDS and Behavior, 2018, 22, 1018-1024.	2.7	22
87	The microbiome and HIV prevention strategies in women. Current Opinion in HIV and AIDS, 2018, 13, 81-87.	3.8	16
88	V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. Cell Reports, 2018, 25, 3123-3135.e6.	6.4	23
89	HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth. Cell Host and Microbe, 2018, 24, 593-599.e3.	11.0	24
90	Exploratory analysis of the ecological variables associated with sexual health profiles in high-risk, sexually-active female learners in rural KwaZulu-Natal. PLoS ONE, 2018, 13, e0195107.	2.5	3

#	Article	IF	CITATIONS
91	Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation. Nature Communications, 2018, 9, 4136.	12.8	11
92	Optimising the accuracy of HIV drug resistance assays. Lancet HIV,the, 2018, 5, e608-e609.	4.7	0
93	Beyond syndromic management: Opportunities for diagnosis-based treatment of sexually transmitted infections in low- and middle-income countries. PLoS ONE, 2018, 13, e0196209.	2.5	81
94	Expert consensus statement on the science of <scp>HIV</scp> in the context of criminal law. Journal of the International AIDS Society, 2018, 21, e25161.	3.0	59
95	Ex vivo HIV entry into blood CD4+ T cells does not predict heterosexual HIV acquisition in women. PLoS ONE, 2018, 13, e0200359.	2.5	5
96	Community-based HIV prevalence in KwaZulu-Natal, South Africa: results of a cross-sectional household survey. Lancet HIV,the, 2018, 5, e427-e437.	4.7	60
97	Case report: mechanisms of HIV elite control in two African women. BMC Infectious Diseases, 2018, 18, 54.	2.9	82
98	Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection. Cell Host and Microbe, 2018, 23, 845-854.e6.	11.0	100
99	Residual T cell activation and skewed CD8+ T cell memory differentiation despite antiretroviral therapy-induced HIV suppression. Clinical Immunology, 2018, 195, 127-138.	3.2	22
100	HIV—No time for complacency. Science, 2018, 360, 1153-1153.	12.6	9
101	HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. PLoS Pathogens, 2018, 14, e1006987.	4.7	71
102	Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. Lancet HIV,the, 2018, 5, e400-e404.	4.7	75
103	Prevention Clinical Trials: Highlights of Evidence and Research. , 2018, , 1713-1723.		0
104	HIV-1 Preexposure Prophylaxis. , 2018, , 886-892.		0
105	CAPRISA 003: Timing of Antiretroviral Initiation in HIV-TB Co-infected Patients—The SAPiT Trial. , 2017, , 107-120.		0
106	Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression. Journal of Virology, 2017, 91, .	3.4	13
107	Secrecy, empowerment and protection: positioning PrEP in KwaZulu-Natal, South Africa. Culture, Health and Sexuality, 2017, 19, 1268-1285.	1.8	18
108	Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study. Lancet HIV,the, 2017, 4, e41-e50.	4.7	220

#	Article	IF	CITATIONS
109	Interleukin 1-Beta (IL-1β) Production by Innate Cells Following TLR Stimulation Correlates With TB Recurrence in ART-Treated HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 213-220.	2.1	16
110	Prevention of HIV in Adolescent Girls and Young Women: Key to an AIDS-Free Generation. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, S17-S26.	2.1	80
111	Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. Science, 2017, 356, 938-945.	12.6	348
112	Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 43-47.	2.1	5
113	Trump's "global gag ruleâ€i implications for human rights and global health. The Lancet Global Health, 2017, 5, e387-e389.	6.3	23
114	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Science Translational Medicine, 2017, 9, .	12.4	81
115	Effect of Antiretroviral Therapy on the Memory and Activation Profiles of B Cells in HIV-Infected African Women. Journal of Immunology, 2017, 198, 1220-1228.	0.8	18
116	Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses. Aids, 2017, 31, 2199-2209.	2.2	13
117	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Science Translational Medicine, 2017, 9, .	12.4	87
118	Early evolution of human leucocyte antigen-associated escape mutations in variable Gag proteins predicts CD4+ decline in HIV-1 subtype C-infected women. Aids, 2017, 31, 191-197.	2.2	2
119	Genital—Systemic Chemokine Gradients and the Risk of HIV Acquisition in Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 318-325.	2.1	64
120	Closing the NIH Fogarty Center threatens US and global health. Lancet, The, 2017, 390, 451.	13.7	2
121	Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope. Journal of Virology, 2017, 91, .	3.4	35
122	Plasma Cytokine Predictors of Tuberculosis Recurrence in Antiretroviral-Treated Human Immunodeficiency Virus-infected Individuals from Durban, South Africa. Clinical Infectious Diseases, 2017, 65, 819-826.	5.8	23
123	Assessing progress with HIV incidence in national cohorts. Lancet HIV,the, 2017, 4, e56-e58.	4.7	2
124	Cervicovaginal Inflammation Facilitates Acquisition of Less Infectious HIV Variants. Clinical Infectious Diseases, 2017, 64, 79-82.	5.8	53
125	Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 734-740.	1.2	6
126	Protocol for a randomised controlled implementation trial of point-of-care viral load testing and task shifting: the Simplifying HIV TREAtment and Monitoring (STREAM) study. BMJ Open, 2017, 7, e017507.	1.9	19

#	Article	IF	CITATIONS
127	Governmental Support of Research. , 2017, , 679-705.		1
128	Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. PLoS Pathogens, 2017, 13, e1006148.	4.7	51
129	Addressing challenges in scaling up TB and HIV treatment integration in rural primary healthcare clinics in South Africa (SUTHI): a cluster randomized controlled trial protocol. Implementation Science, 2017, 12, 129.	6.9	25
130	The Impact of Conditional Cash Transfers in Reducing HIV in Adolescent Girls and Boys (RHIVA): The CAPRISA 007 Matched Pair, Cluster Randomised Controlled Trial. , 2017, , 77-89.		6
131	High mortality rates in men initiated on anti-retroviral treatment in KwaZulu-Natal, South Africa. PLoS ONE, 2017, 12, e0184124.	2.5	13
132	Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathogens, 2017, 13, e1006074.	4.7	33
133	Current status of the HIV epidemic & challenges in prevention. Indian Journal of Medical Research, 2017, 146, 673.	1.0	7
134	Scaling up TB-HIV Integration in Public Health Clinics: Translating Research Findings into Practice. , 2017, , 121-134.		0
135	Prevention Clinical Trials: Highlights of Evidence and Research. , 2017, , 1-11.		Ο
136	Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?. PLoS Biology, 2016, 14, e1002372.	5.6	12
137	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS Pathogens, 2016, 12, e1005520.	4.7	150
138	Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women. Aids, 2016, 30, 1005-1014.	2.2	18
139	Diagnostic Accuracy of the Point-of-Care Xpert HIV-1 Viral Load Assay in a South African HIV Clinic. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, e45-e48.	2.1	37
140	Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials. Antiviral Therapy, 2016, 22, 287-293.	1.0	2
141	Association of Polymorphisms in the Regulatory Region of the Cyclophilin a Gene (PPIA) with Gene Expression and HIV/AIDS Disease Progression. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 465-473.	2.1	8
142	Factors Driving the HIV Epidemic in Southern Africa. Current HIV/AIDS Reports, 2016, 13, 158-169.	3.1	38
143	Social Context of Adherence in an Open-Label 1Â% Tenofovir Gel Trial: Gender Dynamics and Disclosure in KwaZulu-Natal, South Africa. AIDS and Behavior, 2016, 20, 2682-2691.	2.7	12
144	Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site. Journal of Virology, 2016, 90, 10220-10235.	3.4	32

#	Article	IF	CITATIONS
145	Combination HIV prevention options for young women in Africa. African Journal of AIDS Research, 2016, 15, 109-121.	0.9	39
146	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. EBioMedicine, 2016, 12, 196-207.	6.1	34
147	Metabolic Syndrome After HIV Acquisition in South African Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 438-445.	2.1	26
148	Is the UNAIDS target sufficient for HIV control in Botswana?. Lancet HIV,the, 2016, 3, e195-e196.	4.7	8
149	Innate Lymphoid Cells Are Depleted Irreversibly during Acute HIV-1 Infection in the Absence of Viral Suppression. Immunity, 2016, 44, 391-405.	14.3	125
150	Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel. Mucosal Immunology, 2016, 9, 821-833.	6.0	22
151	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. Cell Reports, 2016, 14, 43-54.	6.4	45
152	Inflammatory cytokine biomarkers to identify women with asymptomatic sexually transmitted infections and bacterial vaginosis who are at high risk of HIV infection. Sexually Transmitted Infections, 2016, 92, 186-193.	1.9	50
153	Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial. Contraception, 2016, 93, 25-31.	1.5	15
154	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. Journal of Virology, 2016, 90, 76-91.	3.4	205
155	Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIV-susceptible target cells. Mucosal Immunology, 2016, 9, 194-205.	6.0	205
156	High Burden of Human Papillomavirus (HPV) Infection among Young Women in KwaZulu-Natal, South Africa. PLoS ONE, 2016, 11, e0146603.	2.5	40
157	Modulation of Female Genital Tract-Derived Dendritic Cell Migration and Activation in Response to Inflammatory Cytokines and Toll-Like Receptor Agonists. PLoS ONE, 2016, 11, e0155668.	2.5	5
158	Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. PLoS Pathogens, 2016, 12, e1005742.	4.7	81
159	Efavirenz Dosing: Influence of Drug Metabolizing Enzyme Polymorphisms and Concurrent Tuberculosis Treatment. Antiviral Therapy, 2015, 20, 297-306.	1.0	10
160	Challenges with participant reimbursement: experiences from a post-trial access study. Journal of Medical Ethics, 2015, 41, 909-913.	1.8	6
161	Cost-Effectiveness of Initiating Antiretroviral Therapy at Different Points in TB Treatment in HIV-TB Coinfected Ambulatory Patients in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 576-584.	2.1	10
162	Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women. BMC Infectious Diseases, 2015, 16, 27.	2.9	12

#	Article	IF	CITATIONS
163	Strengthening HIV surveillance in the antiretroviral therapy era: rationale and design of a longitudinal study to monitor HIV prevalence and incidence in the uMgungundlovu District, KwaZulu-Natal, South Africa. BMC Public Health, 2015, 15, 1149.	2.9	33
164	South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication. Retrovirology, 2015, 12, 54.	2.0	19
165	Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 264-269.	2.1	67
166	Antibodies for HIV prevention in young women. Current Opinion in HIV and AIDS, 2015, 10, 183-189.	3.8	9
167	Relationship between female genital tract infections, mucosal interleukinâ€17 production and local T helper type 17 cells. Immunology, 2015, 146, 557-567.	4.4	45
168	Trends in HIV Prevalence in Pregnant Women in Rural South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 289-295.	2.1	51
169	Adolescent girls and young women: key populations for HIV epidemic control. Journal of the International AIDS Society, 2015, 18, 19408.	3.0	361
170	Randomized Cross-Sectional Study to Compare HIV-1 Specific Antibody and Cytokine Concentrations in Female Genital Secretions Obtained by Menstrual Cup and Cervicovaginal Lavage. PLoS ONE, 2015, 10, e0131906.	2.5	26
171	HIV Disease Progression in Seroconvertors from the CAPRISA 004 Tenofovir Gel Pre-exposure Prophylaxis Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 55-61.	2.1	10
172	Tenofovir Gel to Prevent HSV-2 Infection. New England Journal of Medicine, 2015, 373, 1980-1981.	27.0	1
173	Individualised Motivational Counselling to Enhance Adherence to Antiretroviral Therapy is not Superior to Didactic Counselling in South African Patients: Findings of the CAPRISA 058 Randomised Controlled Trial. AIDS and Behavior, 2015, 19, 145-156.	2.7	18
174	HIV-1 Superinfection Resembles Primary Infection. Journal of Infectious Diseases, 2015, 212, 904-908.	4.0	13
175	Overcoming Impediments to Global Implementation of Early Antiretroviral Therapy. New England Journal of Medicine, 2015, 373, 875-876.	27.0	26
176	Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. New England Journal of Medicine, 2015, 373, 530-539.	27.0	80
177	Restoration of CD4+ Responses to Copathogens in HIV-Infected Individuals on Antiretroviral Therapy Is Dependent on T Cell Memory Phenotype. Journal of Immunology, 2015, 195, 2273-2281.	0.8	24
178	Lower concentrations of chemotactic cytokines and soluble innate factors in the lower female genital tract associated with the use of injectable hormonal contraceptive. Journal of Reproductive Immunology, 2015, 110, 14-21.	1.9	38
179	Cenital Inflammation and the Risk of HIV Acquisition in Women. Clinical Infectious Diseases, 2015, 61, 260-269.	5.8	354
180	Hormonal Contraception and the Risk of HIV Acquisition: An Individual Participant Data Meta-analysis. PLoS Medicine, 2015, 12, e1001778.	8.4	170

#	Article	IF	CITATIONS
181	Risk Factors for HIV Acquisition in High Risk Women in a Generalised Epidemic Setting. AIDS and Behavior, 2015, 19, 1305-1316.	2.7	39
182	HIV-Positive Status Disclosure in Patients in Care in Rural South Africa: Implications for Scaling Up Treatment and Prevention Interventions. AIDS and Behavior, 2015, 19, 322-329.	2.7	20
183	Ability To Develop Broadly Neutralizing HIV-1 Antibodies Is Not Restricted by the Germline Ig Gene Repertoire. Journal of Immunology, 2015, 194, 4371-4378.	0.8	85
184	Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis. Journal of Infectious Diseases, 2015, 212, 754-759.	4.0	36
185	Innate Antibacterial Activity in Female Genital Tract Secretions Is Associated with Increased Risk of HIV Acquisition. AIDS Research and Human Retroviruses, 2015, 31, 1153-1159.	1.1	16
186	Epigenetic mechanisms, T-cell activation, and <i>CCR5</i> genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4762-71.	7.1	48
187	Defeating AIDS—advancing global health. Lancet, The, 2015, 386, 171-218.	13.7	234
188	Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nature Medicine, 2015, 21, 1332-1336.	30.7	215
189	Differences in HIV Type 1 Neutralization Breadth in 2 Geographically Distinct Cohorts in Africa. Journal of Infectious Diseases, 2015, 211, 1461-1466.	4.0	7
190	Health-Related Quality of Life Dynamics of HIV-positive South African Women up to ART Initiation: Evidence from the CAPRISA 002 Acute Infection Cohort Study. AIDS and Behavior, 2014, 18, 1114-23.	2.7	16
191	Implementation of Adolescent-Friendly Voluntary Medical Male Circumcision Using a School Based Recruitment Program in Rural KwaZulu-Natal, South Africa. PLoS ONE, 2014, 9, e96468.	2.5	38
192	HIV-1 Specific IgA Detected in Vaginal Secretions of HIV Uninfected Women Participating in a Microbicide Trial in Southern Africa Are Primarily Directed Toward gp120 and gp140 Specificities. PLoS ONE, 2014, 9, e101863.	2.5	36
193	Inclusion of adolescent girls in HIV prevention research – an imperative for an AIDSâ€free generation. Journal of the International AIDS Society, 2014, 17, 19075.	3.0	13
194	Meeting the sexual and reproductive health needs of high-school students in South Africa: Experiences from rural KwaZulu-Natal. South African Medical Journal, 2014, 104, 687.	0.6	11
195	Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 1521-1525.	1.2	14
196	Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial. Trials, 2014, 15, 496.	1.6	9
197	Limited HIV-1 Superinfection in Seroconverters from the CAPRISA 004 Microbicide Trial. Journal of Clinical Microbiology, 2014, 52, 844-848.	3.9	14
198	HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sexually Transmitted Infections, 2014, 90, 363-369.	1.9	34

#	Article	IF	CITATIONS
199	Low rifampicin concentrations in tuberculosis patients with HIV infection. Journal of Infection in Developing Countries, 2014, 8, 987-993.	1.2	35
200	Viral Escape Pathways from Broadly Neutralising Antibodies Targeting the HIV Envelope Cleavage Site Enhance MPER Mediated Neutralisation. AIDS Research and Human Retroviruses, 2014, 30, A20-A21.	1.1	1
201	Appeal to global donors to save the Treatment Action Campaign. Lancet, The, 2014, 384, e62.	13.7	2
202	HIV Infection in High School Students in Rural South Africa: Role of Transmissions Among Students. AIDS Research and Human Retroviruses, 2014, 30, 956-965.	1.1	23
203	Differential Impact of Magnitude, Polyfunctional Capacity, and Specificity of HIV-Specific CD8 ⁺ T Cell Responses on HIV Set Point. Journal of Virology, 2014, 88, 1819-1824.	3.4	36
204	Bacterial Vaginosis and the Risk of Trichomonas vaginalis Acquisition Among HIV-1–Negative Women. Sexually Transmitted Diseases, 2014, 41, 123-128.	1.7	75
205	Y Chromosome and HIV DNA Detection in Vaginal Swabs as Biomarkers of Semen and HIV Exposure in Women. Sexually Transmitted Diseases, 2014, 41, 674-679.	1.7	17
206	Rapid Disease Progression in HIV-1 Subtype C–Infected South African Women. Clinical Infectious Diseases, 2014, 59, 1322-1331.	5.8	46
207	Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection. Retrovirology, 2014, 11, 69.	2.0	27
208	Ratio of Monocytes to Lymphocytes in Peripheral Blood Identifies Adults at Risk of Incident Tuberculosis Among HIV-Infected Adults Initiating Antiretroviral Therapy. Journal of Infectious Diseases, 2014, 209, 500-509.	4.0	99
209	The need for multipurpose prevention technologies in subâ€5aharan Africa. BJOG: an International Journal of Obstetrics and Gynaecology, 2014, 121, 27-34.	2.3	35
210	Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies. BJOG: an International Journal of Obstetrics and Gynaecology, 2014, 121, 53-61.	2.3	7
211	Mervyn W. Susser - His Contributions to the Acquired Immune Deficiency Syndrome Response in South Africa. Paediatric and Perinatal Epidemiology, 2014, 28, 473-475.	1.7	0
212	Sensitive Tenofovir Resistance Screening of HIV-1 From the Genital and Blood Compartments of Women With Breakthrough Infections in the CAPRISA 004 Tenofovir Gel Trial. Journal of Infectious Diseases, 2014, 209, 1916-1920.	4.0	13
213	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature, 2014, 509, 55-62.	27.8	681
214	TRIM5α and TRIM22 Are Differentially Regulated According to HIV-1 Infection Phase and Compartment. Journal of Virology, 2014, 88, 4291-4303.	3.4	21
215	Nelson R. Mandela (1918–2013). Science, 2014, 343, 150-150.	12.6	4
216	Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study. Sexually Transmitted Infections, 2014, 90, 580-587.	1.9	173

#	Article	IF	CITATIONS
217	Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies. Cell Host and Microbe, 2014, 16, 304-313.	11.0	137
218	Nef-mediated down-regulation of CD4 and HLA class I in HIV-1 subtype C infection: Association with disease progression and influence of immune pressure. Virology, 2014, 468-470, 214-225.	2.4	20
219	Disclosure of Microbicide Gel Use to Sexual Partners: Influence on Adherence in the CAPRISA 004 Trial. AIDS and Behavior, 2014, 18, 849-854.	2.7	44
220	Measuring Adherence by Visual Inspection of Returned Empty Gel Applicators in the CAPRISA 004 Microbicide Trial. AIDS and Behavior, 2014, 18, 820-825.	2.7	7
221	Monitoring Microbicide Gel Use with Real-Time Notification of the Container's Opening Events: Results of the CAPRISA Wisebag Study. AIDS and Behavior, 2014, 18, 833-840.	2.7	10
222	Adherence in the CAPRISA 004 Tenofovir Gel Microbicide Trial. AIDS and Behavior, 2014, 18, 811-819.	2.7	21
223	Impact of an Adherence Intervention on the Effectiveness of Tenofovir Gel in the CAPRISA 004 Trial. AIDS and Behavior, 2014, 18, 841-848.	2.7	20
224	Assessing Adherence in the CAPRISA 004 Tenofovir Gel HIV Prevention Trial: Results of a Nested Case–Control Study. AIDS and Behavior, 2014, 18, 826-832.	2.7	9
225	The Preventive Misconception: Experiences from CAPRISA 004. AIDS and Behavior, 2014, 18, 1746-1752.	2.7	8
226	Impact of Antiretroviral Therapy on Health-Related Quality of Life among South African Women in the CAPRISA 002 Acute Infection Study. AIDS and Behavior, 2014, 18, 1801-1807.	2.7	18
227	Prevalence of HIV, HSV-2 and pregnancy among high school students in rural KwaZulu-Natal, South Africa: a bio-behavioural cross-sectional survey. Sexually Transmitted Infections, 2014, 90, 620-626.	1.9	47
228	The HIV Epidemic in Southern Africa – Is an AIDS-Free Generation Possible?. Current HIV/AIDS Reports, 2014, 11, 99-108.	3.1	21
229	Changes to Antiretroviral Drug Regimens during Integrated TB–HIV Treatment: Results of the Sapit Trial. Antiviral Therapy, 2014, 19, 161-169.	1.0	16
230	High Rates of Tuberculosis in Patients Accessing HAART in Rural South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 438-446.	2.1	14
231	Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. International Journal of Tuberculosis and Lung Disease, 2014, 18, 147-154.	1.2	29
232	Safety of Tenofovir Gel, a Vaginal Microbicide, in South African Women: Results of the Caprisa 004 Trial. Antiviral Therapy, 2013, 18, 301-310.	1.0	21
233	The Global HIV Epidemic: Current Status and Challenges. Current HIV/AIDS Reports, 2013, 10, 111-112.	3.1	10
234	Comparison of Viral Env Proteins from Acute and Chronic Infections with Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and Suggests a New Strategy for Immunogen Design. Journal of Virology, 2013, 87, 7218-7233.	3.4	119

#	Article	IF	CITATIONS
235	Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. Virology Journal, 2013, 10, 347.	3.4	14
236	Microbicides for the prevention of sexually transmitted HIV infection. Expert Review of Anti-Infective Therapy, 2013, 11, 12-23.	4.4	11
237	HIV pre-exposure prophylaxis in injecting drug users. Lancet, The, 2013, 381, 2060-2062.	13.7	17
238	Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines. Vaccine, 2013, 31, B204-B208.	3.8	26
239	Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: Results from the CAPRISA 004 trial. Antiviral Research, 2013, 99, 405-408.	4.1	2
240	Neither Microbial Translocation Nor TLR Responsiveness Are Likely Explanations for Preexisting Immune Activation in Women Who Subsequently Acquired HIV in CAPRISA 004. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 294-298.	2.1	6
241	Microbicides for Prevention of HIV Infection: Clinical Efficacy Trials. Current Topics in Microbiology and Immunology, 2013, 383, 97-115.	1.1	10
242	Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes. PLoS Pathogens, 2013, 9, e1003738.	4.7	190
243	The changing epidemiology of HIV in 2013. Current Opinion in HIV and AIDS, 2013, 8, 1.	3.8	78
244	When to start antiretroviral therapy during tuberculosis treatment?. Current Opinion in Infectious Diseases, 2013, 26, 35-42.	3.1	37
245	Multiple Pathways of Escape from HIV Broadly Cross-Neutralizing V2-Dependent Antibodies. Journal of Virology, 2013, 87, 4882-4894.	3.4	65
246	Antiâ€retrovirals for treatment and prevention – time for new paradigms in our response to the <scp>HIV/AIDS</scp> epidemic?. Developing World Bioethics, 2013, 13, ii-iii.	0.9	6
247	Topical Microbicides—What's New?. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, S144-S149.	2.1	17
248	Rapid, complex adaptation of transmitted HIV-1 full-length genomes in subtype C-infected individuals with differing disease progression. Aids, 2013, 27, 507-518.	2.2	14
249	Appropriateness of Hydroxyethylcellulose Gel as a Placebo Control in Vaginal Microbicide Trials. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 120-125.	2.1	19
250	Changes in Natural Killer Cell Activation and Function during Primary HIV-1 Infection. PLoS ONE, 2013, 8, e53251.	2.5	49
251	Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial. PLoS ONE, 2013, 8, e56400.	2.5	9
252	No Evidence for Selection of HIV-1 with Enhanced Gag-Protease or Nef Function among Breakthrough Infections in the CAPRISA 004 Tenofovir Microbicide Trial. PLoS ONE, 2013, 8, e71758.	2.5	11

#	Article	IF	CITATIONS
253	Development of Methods for Cross-Sectional HIV Incidence Estimation in a Large, Community Randomized Trial. PLoS ONE, 2013, 8, e78818.	2.5	33
254	Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. Journal of Clinical Investigation, 2013, 123, 380-93.	8.2	165
255	Temporal Association of HLA-B*81:01- and HLA-B*39:10-Mediated HIV-1 p24 Sequence Evolution with Disease Progression. Journal of Virology, 2012, 86, 12013-12024.	3.4	20
256	Genital Tract Inflammation During Early HIV-1 Infection Predicts Higher Plasma Viral Load Set Point in Women. Journal of Infectious Diseases, 2012, 205, 194-203.	4.0	67
257	Mucosal Escherichia coli Bactericidal Activity and Immune Mediators Are Associated With HIV-1 Seroconversion in Women Participating in the HPTN 035 Trial. Journal of Infectious Diseases, 2012, 206, 1931-1935.	4.0	21
258	Intersubtype Differences in the Effect of a Rare p24 Gag Mutation on HIV-1 Replicative Fitness. Journal of Virology, 2012, 86, 13423-13433.	3.4	9
259	Symptomatic Vaginal Discharge Is a Poor Predictor of Sexually Transmitted Infections and Genital Tract Inflammation in High-Risk Women in South Africa. Journal of Infectious Diseases, 2012, 206, 6-14.	4.0	171
260	Preexposure Prophylaxis for HIV Prevention. New England Journal of Medicine, 2012, 367, 462-465.	27.0	9
261	Innate Immune Activation Enhances HIV Acquisition in Women, Diminishing the Effectiveness of Tenofovir Microbicide Gel. Journal of Infectious Diseases, 2012, 206, 993-1001.	4.0	137
262	Increased Memory Differentiation Is Associated with Decreased Polyfunctionality for HIV but Not for Cytomegalovirus-Specific CD8+T Cells. Journal of Immunology, 2012, 189, 3838-3847.	0.8	18
263	A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Expert Opinion on Investigational Drugs, 2012, 21, 695-715.	4.1	22
264	Phase I Safety and Immunogenicity Evaluations of an Alphavirus Replicon HIV-1 Subtype C <i>gag</i> Vaccine in Healthy HIV-1-Uninfected Adults. Vaccine Journal, 2012, 19, 1651-1660.	3.1	60
265	An AIDS-Free Generation?. Science, 2012, 337, 133-133.	12.6	8
266	Declining adherence is a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial. Aids, 2012, 26, 2261.	2.2	4
267	An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure. Clinical Trials, 2012, 9, 377-384.	1.6	2
268	Design challenges facing clinical trials of the effectiveness of new HIV-prevention technologies. Aids, 2012, 26, 529-532.	2.2	9
269	Natural killer cell function in women at high risk for HIV acquisition. Aids, 2012, 26, 1745-1753.	2.2	14
270	Preservation HIV-1–Specific IFNγ+ CD4+ T-Cell Responses in Breakthrough Infections After Exposure to Tenofovir Gel in the CAPRISA 004 Microbicide Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 124-127.	2.1	19

#	Article	IF	CITATIONS
271	The Immune Reconstitution Inflammatory Syndrome After Antiretroviral Therapy Initiation in Patients With Tuberculosis: Findings From the SAPiT Trial. Annals of Internal Medicine, 2012, 157, 313.	3.9	101
272	Antiretroviral prophylaxis for HIV prevention reaches a key milestone. Lancet, The, 2012, 379, 2047-2048.	13.7	8
273	Health in South Africa: changes and challenges since 2009. Lancet, The, 2012, 380, 2029-2043.	13.7	396
274	Sustainability of task-shifting for antiretroviral treatment. Lancet, The, 2012, 380, 1907-1908.	13.7	5
275	HIV Incidence in Young Girls in KwaZulu-Natal, South Africa-Public Health Imperative for Their Inclusion in HIV Biomedical Intervention Trials. AIDS and Behavior, 2012, 16, 1870-1876.	2.7	54
276	Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape. Nature Medicine, 2012, 18, 1688-1692.	30.7	273
277	HIV prevalence among high school learners - opportunities for schools-based HIV testing programmes and sexual reproductive health services. BMC Public Health, 2012, 12, 231.	2.9	31
278	HIV prevention. , 2012, , 113-121.		0
279	The Development of CD4 Binding Site Antibodies during HIV-1 Infection. Journal of Virology, 2012, 86, 7588-7595.	3.4	123
280	CAPRISA 004 Tenofovir Microbicide Trial: No Impact of Tenofovir Gel on the HIV Transmission Bottleneck. Journal of Infectious Diseases, 2012, 206, 35-40.	4.0	16
281	The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. European Journal of Clinical Pharmacology, 2012, 68, 689-695.	1.9	50
282	Empowering women in human immunodeficiency virus prevention. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2012, 26, 487-493.	2.8	12
283	Overview of microbicides for the prevention of human immunodeficiency virus. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2012, 26, 427-439.	2.8	34
284	Implementing microbicides in low-income countries. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2012, 26, 495-501.	2.8	8
285	The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4 ⁺ T Cell Decline and High Viral Load during Acute Infection. Journal of Virology, 2011, 85, 4828-4840.	3.4	441
286	Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop. Journal of Virology, 2011, 85, 3128-3141.	3.4	151
287	Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals. Journal of Virology, 2011, 85, 11502-11519.	3.4	168
288	Co-enrollment in multiple HIV prevention trials — Experiences from the CAPRISA 004 Tenofovir gel trial. Contemporary Clinical Trials, 2011, 32, 333-338.	1.8	27

#	Article	IF	CITATIONS
289	Community-based intervention to increase HIV testing and case detection in people aged 16–32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. Lancet Infectious Diseases, The, 2011, 11, 525-532.	9.1	204
290	HIV prevention transformed: the new prevention research agenda. Lancet, The, 2011, 378, 269-278.	13.7	238
291	Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet, The, 2011, 378, 279-281.	13.7	220
292	Antiretroviral prophylaxis: a defining moment in HIV control. Lancet, The, 2011, 378, e23-e25.	13.7	84
293	Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. Aids, 2011, 25, 957-966.	2.2	215
294	Contraceptive Choices, Pregnancy Rates, and Outcomes in a Microbicide Trial. Obstetrics and Gynecology, 2011, 118, 895-904.	2.4	32
295	Stigma impedes AIDS prevention. Nature, 2011, 474, 29-31.	27.8	25
296	Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials, 2011, 12, 67.	1.6	33
297	Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opinion on Drug Safety, 2011, 10, 559-574.	2.4	16
298	Duffy-Null–Associated Low Neutrophil Counts Influence HIV-1 Susceptibility in High-Risk South African Black Women. Clinical Infectious Diseases, 2011, 52, 1248-1256.	5.8	69
299	Integration of Antiretroviral Therapy with Tuberculosis Treatment. New England Journal of Medicine, 2011, 365, 1492-1501.	27.0	451
300	Virological and Immunological Factors Associated with HIV-1 Differential Disease Progression in HLA-B*58:01-Positive Individuals. Journal of Virology, 2011, 85, 7070-7080.	3.4	25
301	The future role of rectal and vaginal microbicides to prevent HIV infection in heterosexual populations: implications for product development and prevention. Sexually Transmitted Infections, 2011, 87, 646-653.	1.9	27
302	HIV-Associated Tuberculosis. Clinical and Developmental Immunology, 2011, 2011, 1-8.	3.3	14
303	Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. International Journal of Epidemiology, 2011, 40, 922-930.	1.9	109
304	Case 15-2011. New England Journal of Medicine, 2011, 364, 1956-1964.	27.0	0
305	Association of polymorphisms in the LEDCF/p75 gene (PSIP1) with susceptibility to HIV-1 infection and disease progression. Aids, 2011, 25, 1711-1719.	2.2	22
306	Experience in international clinical research: the HIV Prevention Trials Network. Clinical Investigation, 2011, 1, 1609-1618.	0.0	14

#	Article	IF	CITATIONS
307	Epidemiological Impact of Tenofovir Gel on the HIV Epidemic in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 207-210.	2.1	51
308	Short Communication Decreased Incidence of Dual Infections in South African Subtype C-Infected Women Compared to a Cohort Ten Years Earlier. AIDS Research and Human Retroviruses, 2011, 27, 1167-1172.	1.1	7
309	Association of TRIM22 with the Type 1 Interferon Response and Viral Control during Primary HIV-1 Infection. Journal of Virology, 2011, 85, 208-216.	3.4	66
310	Isolation of a Monoclonal Antibody That Targets the Alpha-2 Helix of gp120 and Represents the Initial Autologous Neutralizing-Antibody Response in an HIV-1 Subtype C-Infected Individual. Journal of Virology, 2011, 85, 7719-7729.	3.4	54
311	Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting. PLoS ONE, 2011, 6, e23532.	2.5	137
312	Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. Aids, 2010, 24, 819-831.	2.2	195
313	Adaptive changes in HIV-1 subtype C proteins during early infection are driven by changes in HLA-associated immune pressure. Virology, 2010, 396, 213-225.	2.4	26
314	Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. Virology, 2010, 402, 187-196.	2.4	95
315	Screening for â€~windowâ€period' acute HIV infection among pregnant women in rural South Africa. HIV Medicine, 2010, 11, 661-665.	2.2	30
316	AIDS research must link to local policy. Nature, 2010, 463, 733-734.	27.8	13
317	The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. South African Medical Journal, 2010, 100, 808.	0.6	10
318	Inclusion of Adolescent Women in Microbicide Trials: A Public Health Imperative!. Public Health Ethics, 2010, 3, 39-50.	1.0	13
319	Fluidity of HIV-1-Specific T-Cell Responses during Acute and Early Subtype C HIV-1 Infection and Associations with Early Disease Progression. Journal of Virology, 2010, 84, 12018-12029.	3.4	26
320	HIV-Selectest Enzyme Immunoassay and Rapid Test: Ability To Detect Seroconversion following HIV-1 Infection. Journal of Clinical Microbiology, 2010, 48, 281-285.	3.9	9
321	Preventing HIV Infection in Women: A Global Health Imperative. Clinical Infectious Diseases, 2010, 50, S122-S129.	5.8	97
322	Uptake of provider-initiated HIV testing and counseling among women attending an urban sexually transmitted disease clinic in South Africa – missed opportunities for early diagnosis of HIV infection. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2010, 22, 533-537.	1.2	35
323	APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. Aids, 2010, 24, 195-204.	2.2	61
324	Results of effectiveness trials of PRO 2000 gel: lessons for future microbicide trials. Future Microbiology, 2010, 5, 527-529.	2.0	19

#	Article	IF	CITATIONS
325	Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science, 2010, 329, 1168-1174.	12.6	2,239
326	Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy. New England Journal of Medicine, 2010, 362, 697-706.	27.0	608
327	Microbicides & their implications in HIV prevention. Indian Journal of Medical Research, 2010, 132, 656-9.	1.0	7
328	Re: "Enhancement of HIV Infection by Cellulose Sulfate,―by Tao et al AIDS Research and Human Retroviruses, 2009, 25, 373-373.	1.1	1
329	Human TRIM5α Expression Levels and Reduced Susceptibility to HIVâ€1 Infection. Journal of Infectious Diseases, 2009, 199, 1657-1663.	4.0	46
330	Association of HIV-Specific and Total CD8+ T Memory Phenotypes in Subtype C HIV-1 Infection with Viral Set Point. Journal of Immunology, 2009, 182, 4751-4761.	0.8	75
331	Commentary: Spatial clustering of HIV infection: providing clues for effective HIV prevention. International Journal of Epidemiology, 2009, 38, 1016-1017.	1.9	8
332	Quantitating the Multiplicity of Infection with Human Immunodeficiency Virus Type 1 Subtype C Reveals a Non-Poisson Distribution of Transmitted Variants. Journal of Virology, 2009, 83, 3556-3567.	3.4	354
333	Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection. PLoS Pathogens, 2009, 5, e1000598.	4.7	213
334	Interleukinâ€10 Promoter Polymorphisms Influence HIVâ€1 Susceptibility and Primary HIVâ€1 Pathogenesis. Journal of Infectious Diseases, 2009, 200, 448-452.	4.0	72
335	Broad Neutralization of Human Immunodeficiency Virus Type 1 Mediated by Plasma Antibodies against the gp41 Membrane Proximal External Region. Journal of Virology, 2009, 83, 11265-11274.	3.4	93
336	Human Immunodeficiency Virus-Specific Gamma Interferon Enzyme-Linked Immunospot Assay Responses Targeting Specific Regions of the Proteome during Primary Subtype C Infection Are Poor Predictors of the Course of Viremia and Set Point. Journal of Virology, 2009, 83, 470-478.	3.4	63
337	Salim "Slim―Abdool Karim: Attacking AIDS in South Africa. Journal of Experimental Medicine, 2009, 206, 2306-2307.	8.5	0
338	Scientists stand by decision to join Mbeki's AIDS panel. Nature, 2009, 457, 379-379.	27.8	1
339	Disclosure of HIV status: experiences of patients enrolled in an integrated TB and HAART pilot programme in South Africa. African Journal of AIDS Research, 2009, 8, 1-6.	0.9	19
340	HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet, The, 2009, 374, 921-933.	13.7	414
341	Achieving the health Millennium Development Goals for South Africa: challenges and priorities. Lancet, The, 2009, 374, 1023-1031.	13.7	214
342	PRO 2000: next steps for microbicide development. Future Virology, 2009, 4, 317-320.	1.8	2

#	Article	IF	CITATIONS
343	Antiretroviral prophylaxis for the prevention of HIV infection: future implementation challenges. HIV Therapy, 2009, 3, 3-6.	0.6	29
344	Interventions with youth in high-prevalence areas. , 2009, , 407-443.		9
345	Conserved positive selection signals in gp41 across multiple subtypes and difference in selection signals detectable in gp41 sequences sampled during acute and chronic HIV-1 subtype C infection. Virology Journal, 2008, 5, 141.	3.4	4
346	Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia. Journal of Virology, 2008, 82, 12449-12463.	3.4	548
347	Human Immunodeficiency Virus Type 1 gp41 Antibodies That Mask Membrane Proximal Region Epitopes: Antibody Binding Kinetics, Induction, and Potential for Regulation in Acute Infection. Journal of Virology, 2008, 82, 115-125.	3.4	108
348	Apnea and its possible relationship to immunization in ex-premature infants. Vaccine, 2008, 26, 3410-3413.	3.8	15
349	The influence of AIDS stigma and discrimination and social cohesion on HIV testing and willingness to disclose HIV in rural KwaZulu-Natal, South Africa. Global Public Health, 2008, 3, 351-365.	2.0	42
350	HIV Risk Behaviors in Sub-Saharan Africa and Northern Thailand: Baseline Behavioral Data From Project Accept. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 309-319.	2.1	44
351	Relationship between Levels of Inflammatory Cytokines in the Genital Tract and CD4 ⁺ Cell Counts in Women with Acute HIV†Infection. Journal of Infectious Diseases, 2008, 198, 710-714.	4.0	71
352	Transmission of HIV-1 CTL Escape Variants Provides HLA-Mismatched Recipients with a Survival Advantage. PLoS Pathogens, 2008, 4, e1000033.	4.7	129
353	The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection. Journal of Virology, 2008, 82, 1860-1869.	3.4	142
354	HIV Transmission and its Prevention in Africa. , 2008, , 565-575.		0
355	Anaemia in Acute HIV-1 Subtype C Infection. PLoS ONE, 2008, 3, e1626.	2.5	15
356	Establishing a Cohort at High Risk of HIV Infection in South Africa: Challenges and Experiences of the CAPRISA 002 Acute Infection Study. PLoS ONE, 2008, 3, e1954.	2.5	175
357	Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection. Journal of Virology, 2007, 81, 6187-6196.	3.4	262
358	Response to Brown et al., †Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe'. Aids, 2007, 21, 2356-2357.	2.2	0
359	Utilizing nucleic acid amplification to identify acute HIV infection. Aids, 2007, 21, 653-655.	2.2	11
360	Longitudinal Analysis of HIV Type 1 Subtype C Envelope Sequences from South Africa. AIDS Research and Human Retroviruses, 2007, 23, 316-321.	1.1	25

#	Article	IF	CITATIONS
361	Practice Brief: Adolescents and HIV Clinical Trials: Ethics, Culture, and Context. Journal of the Association of Nurses in AIDS Care, 2007, 18, 78-82.	1.0	25
362	Global Epidemiology of HIV-AIDS. Infectious Disease Clinics of North America, 2007, 21, 1-17.	5.1	24
363	Diverse approaches useful for microbicide trials. Nature, 2007, 449, 24-24.	27.8	8
364	Opportunities for treating sexually transmitted infections and reducing HIV risk in rural South Africa. Journal of Advanced Nursing, 2007, 60, 377-383.	3.3	19
365	Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatrics, 2007, 7, 13.	1.7	159
366	HIV incidence estimates are key to understanding the changing HIV epidemic in South Africa. South Africa African Medical Journal, 2007, 97, 190.	0.6	2
367	HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet, The, 2006, 368, 489-504.	13.7	496
368	Enrolling Adolescents in Research on HIV and Other Sensitive Issues: Lessons from South Africa. PLoS Medicine, 2006, 3, e180.	8.4	43
369	Modeling the Impact of a Partially Effective HIV Vaccine on HIV Infection and Death Among Women and Infants in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 219-225.	2.1	26
370	Durban 2000 to Toronto 2006: The evolving challenges in implementing AIDS treatment in Africa. Aids, 2006, 20, N7-N9.	2.2	6
371	Ritonavir/saquinavir safety concerns curtail antiretroviral therapy options for tuberculosis–HIV-co-infected patients in resource-constrained settings. Aids, 2006, 20, 302-303.	2.2	9
372	Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa. Journal of Virology, 2006, 80, 11776-11790.	3.4	334
373	TB treatment outcomes following directly-observed treatment at an urban outpatient specialist TB facility in South Africa. Tropical Doctor, 2006, 36, 23-25.	0.5	6
374	The Impact of Incident and Prevalent Herpes Simplex Virus-2 Infection on the Incidence of HIV-1 Infection Among Commercial Sex Workers in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 333-339.	2.1	67
375	Knowledge and acceptability of HAART among TB patients in Durban, South Africa. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2005, 17, 767-772.	1.2	10
376	Short Communication: Viral Dynamics and CD4+ T Cell Counts in Subtype C Human Immunodeficiency Virus Type 1-Infected Individuals from Southern Africa. AIDS Research and Human Retroviruses, 2005, 21, 285-291.	1.1	24
377	The African Experience. , 2005, , 351-373.		2
378	Incidence of HIVâ€1 Dual Infection and Its Association with Increased Viral Load Set Point in a Cohort of HIVâ€1 Subtype C–Infected Female Sex Workers. Journal of Infectious Diseases, 2004, 190, 1355-1359.	4.0	119

#	Article	IF	CITATIONS
379	Hierarchical Targeting of Subtype C Human Immunodeficiency Virus Type 1 Proteins by CD8 + T Cells: Correlation with Viral Load. Journal of Virology, 2004, 78, 3233-3243.	3.4	202
380	A Pilot Study of Once-Daily Antiretroviral Therapy Integrated With Tuberculosis Directly Observed Therapy in a Resource-Limited Setting. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 929-934.	2.1	58
381	Novel and Promiscuous CTL Epitopes in Conserved Regions of Gag Targeted by Individuals with Early Subtype C HIV Type 1 Infection from Southern Africa. Journal of Immunology, 2004, 173, 4607-4617.	0.8	49
382	Ethical Challenges in International HIV Prevention Research. Accountability in Research, 2004, 11, 49-61.	2.4	23
383	Utility of Tuberculosis Directly Observed Therapy Programs as Sites for Access to and Provision of Antiretroviral Therapy in Resource-Limited Countries. Clinical Infectious Diseases, 2004, 38, S421-S428.	5.8	27
384	Treatment of maternal syphilis in rural South Africa: effect of multiple doses of benzathine penicillin on pregnancy loss. Tropical Medicine and International Health, 2004, 9, 1216-1221.	2.3	20
385	Dual HIV-1 infection associated with rapid disease progression. Lancet, The, 2004, 363, 619-622.	13.7	189
386	Medical education after the first decade of democracy in South Africa. Lancet, The, 2004, 363, 1395.	13.7	8
387	Implementing antiretroviral therapy in resource-constrained settings. Aids, 2004, 18, 975-979.	2.2	33
388	Heterosexual transmission of multiple highly conserved viral variants in HIV-1 subtype C-infected seronegative women. Aids, 2004, 18, 2096-2098.	2.2	6
389	Antiretroviral therapy: challenges and options in South Africa. Lancet, The, 2003, 362, 1499.	13.7	5
390	Characterization and Selection of HIV-1 Subtype C Isolates for Use in Vaccine Development. AIDS Research and Human Retroviruses, 2003, 19, 133-144.	1.1	113
391	The Acceptability of an Investigational Vaginal Microbicide, PRO 2000 Gel, among Women in a Phase I Clinical Trial. Journal of Women's Health, 2003, 12, 655-666.	3.3	91
392	Impact of on-site testing for maternal syphilis on treatment delays, treatment rates, and perinatal mortality in rural South Africa: a randomised controlled trial. Sexually Transmitted Infections, 2003, 79, 208-213.	1.9	55
393	Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. Aids, 2003, 17, 321-329.	2.2	83
394	Who infects whom? HIV-1 concordance and discordance among migrant and non-migrant couples in South Africa. Aids, 2003, 17, 2245-2252.	2.2	249
395	The Impact of Migration on HIV-1 Transmission in South Africa. Sexually Transmitted Diseases, 2003, 30, 149-156.	1.7	362
396	Safety and Trough Concentrations of Nevirapine Prophylaxis Given Daily, Twice Weekly, or Weekly in Breast-Feeding Infants From Birth to 6 Months. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 482-490.	2.1	59

#	Article	IF	CITATIONS
397	High Incidence of HIV-1 in South Africa Using a Standardized Algorithm for Recent HIV Seroconversion. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 531-535.	2.1	46
398	Regional Clustering of Shared Neutralization Determinants on Primary Isolates of Clade C Human Immunodeficiency Virus Type 1 from South Africa. Journal of Virology, 2002, 76, 2233-2244.	3.4	111
399	The evolving HIV epidemic in South Africa. International Journal of Epidemiology, 2002, 31, 37-40.	1.9	54
400	Incidence of Sexually Transmitted Infections Among HIV-Positive Sex Workers in KwaZulu-Natal, South Africa. Sexually Transmitted Diseases, 2002, 29, 721-724.	1.7	18
401	A randomized controlled trial of azithromycin versus doxycycline/ciprofloxacin for the syndromic management of sexually transmitted infections in a resource-poor setting. Journal of Antimicrobial Chemotherapy, 2002, 49, 875-878.	3.0	31
402	Vertical HIV transmission in South Africa: translating research into policy and practice. Lancet, The, 2002, 359, 992-993.	13.7	21
403	Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet, The, 2002, 360, 971-977.	13.7	755
404	The fate of free male condoms distributed to the public in South Africa. Aids, 2001, 15, 789-793.	2.2	21
405	Clinical testing of microbicides: a global research priority. Aids, 2001, 15, 929-930.	2.2	1
406	Estimating HIV incidence rates from age prevalence data in epidemic situations. Statistics in Medicine, 2001, 20, 2003-2016.	1.6	66
407	Conserved Domains of Subtype C Nef from South African HIV Type 1-Infected Individuals Include Cytotoxic T Lymphocyte Epitope-Rich Regions. AIDS Research and Human Retroviruses, 2001, 17, 1681-1687.	1.1	20
408	Microbicide Research and Development—Where To?. HIV Clinical Trials, 2001, 2, 185-192.	2.0	6
409	Characterization of Full-Length HIV Type 1 Subtype C Sequences from South Africa. AIDS Research and Human Retroviruses, 2001, 17, 1527-1531.	1.1	52
410	Estimating HIV incidence rates from age prevalence data in epidemic situations. Statistics in Medicine, 2001, 20, 2003-2016.	1.6	3
411	Challenges in the conduct of vaginal microbicide effectiveness trials in the developing world. Aids, 2000, 14, 2553-2557.	2.2	40
412	Availability of Condoms in Urban and Rural Areas of KwaZulu-Natal, South Africa. Sexually Transmitted Diseases, 2000, 27, 353-357.	1.7	18
413	Syndrome packets and health worker training improve sexually transmitted disease case management in rural South Africa: randomized controlled trial. Aids, 2000, 14, 2769-2779.	2.2	43
414	Globalization, Ethics, and AIDS Vaccines. Science, 2000, 288, 2129-2129.	12.6	5

#	Article	IF	CITATIONS
415	Inadequate Treatment for Sexually Transmitted Diseases in the South African Private Health Sector. International Journal of STD and AIDS, 1999, 10, 324-327.	1.1	26
416	Short course antiretroviral regimens to reduce maternal transmission of HIV. BMJ: British Medical Journal, 1999, 318, 479-480.	2.3	11
417	Phase 1 trial of nonoxynol-9 film among sex workers in South Africa. Aids, 1999, 13, 1511-1515.	2.2	44
418	STD Syndrome Packets: Improving Syndromic Management of Sexually Transmitted Diseases In Developing Countries. Sexually Transmitted Diseases, 1999, 26, 152-156.	1.7	14
419	HIV infection and asymptomatic sexually transmitted infections in a rural South African community. International Journal of STD and AIDS, 1998, 9, 548-550.	1.1	37
420	Sexually Transmitted Infections Among Sex Workers in KwaZulu-Natal, South Africa. Sexually Transmitted Diseases, 1998, 25, 346-349.	1.7	81
421	Improving quality of sexually transmitted disease case management in rural South Africa. Aids, 1998, 12, 2329-2335.	2.2	38
422	Sexually Transmitted Disease Syndromes in Rural South Africa. Sexually Transmitted Diseases, 1998, 25, 20-23.	1.7	29
423	South Africa. Lancet, The, 1997, 349, 1537-1545.	13.7	19
424	Potential savings from generic prescribing and generic substitution in South Africa. Health Policy and Planning, 1996, 11, 198-202.	2.7	39
425	Sex difference in measles fatality after introduction of new measles vaccine. Lancet, The, 1994, 343, 1366-1367.	13.7	11
426	Seroprevalence of HIV infection in rural South Africa. Aids, 1992, 6, 1535-1540.	2.2	93
427	Household Clustering and Intra-Household Transmission Patterns of Hepatitis B Virus Infection in South Africa. International Journal of Epidemiology, 1991, 20, 495-503.	1.9	46
428	The Prevalence and Transmission of Hepatitis B Virus Infection in Urban, Rural and Institutionalized Black Children of Natal/KwaZulu, South Africa. International Journal of Epidemiology, 1988, 17, 168-173.	1.9	44
429	Socio-Medical Indicators of Health in South Africa. International Journal of Health Services, 1986, 16, 163-178.	2.5	13
430	Overview of the book. , 0, , 45-54.		2
431	New prevention strategies under development and investigation. , 0, , 268-282.		3

432 The future of the HIV epidemic in South Africa. , 0, , 585-590.

#	Article	IF	CITATIONS
433	Cost-Effectiveness of Point-of-Care Testing with Task-Shifting for HIV Care in South Africa: A Modelling Study. SSRN Electronic Journal, 0, , .	0.4	0
434	Impact of SARS-CoV-2 variants of concern on Covid-19 epidemic in South Africa. Transactions of the Royal Society of South Africa, 0, , 1-4.	1.1	2
435	HIV Coinfection Provides Insights for the Design of Vaccine Cocktails to Elicit Broadly Neutralizing Antibodies. Journal of Virology, 0, , .	3.4	0